Product Image

No-Flush Niacin 500 mg

Source Naturals
4.7
★ ★ ★ ★ ★
(1597 ratings)
Niacin 500 mg
Product Image
Score73
A well-labeled, affordable no-flush niacin derivative with better comfort but less dependable lipid activity than nicotinic acid.
How scoring works
Quantity:60 Tablet(s) • (60 servings)
Goals:
Cardiovascular Support
Heart Health

Score 73

A well-labeled, affordable no-flush niacin derivative with better comfort but less dependable lipid activity than nicotinic acid.
How scoring works
$9.95($0.16 per serving)
Pure Formulas
$ 10.21
iHerb
$ 11.08
iHerb
$ 11.08
Vitacost
$ 9.95
Report prices

Analysis

Inositol hexanicotinate is designed to provide niacin with less acute flushing than nicotinic acid. The derivative and associated inositol amount are clearly listed.

The large label amount does not guarantee the lipid effects of an equivalent nicotinic acid dose. It is also not niacinamide, so the stronger skin-barrier rationale for that form does not directly apply.

The product suits users who value tolerability and understand its narrower evidence base. Anyone seeking cholesterol management should use a clinically directed approach rather than relying on the no-flush name.

Who is it for
  • Adults prioritizing low flushing risk
  • Users specifically seeking inositol hexanicotinate
  • People wanting a simple niacin derivative
Best for
  • Flush-sensitive vitamin B3 use
  • Inositol hexanicotinate supplementation
  • General metabolic support

Pros

  • No-flush form is clearly identified
  • Focused formula
  • Good practical value

Cons

  • Lipid effects are less reliable than nicotinic acid
  • Weak direct skin alignment
  • No specialized release technology

Warnings

  • Do not use it as a substitute for clinician-managed lipid treatment
  • The large label amount may not equal the same active niacin exposure as nicotinic acid
  • Regular high-dose niacin derivatives may still affect liver enzymes or glucose in susceptible users

Nutrient quality

76 High impact

Inositol hexanicotinate is a recognizable low-flush form with a substantial stated amount. Uncertain niacin release and weaker lipid-related performance limit the value of that dose.

Ingredient transparency

70 High impact

Most stated amounts and the serving size are clear without a conventional proprietary blend. Form ambiguity, overlapping entries, or missing non-active ingredients leave important label gaps.

Customer satisfaction

71 High impact

The average rating is very strong, with a large review count supporting the signal. No detailed reviews are supplied to assess repeated complaints or intended-use experiences.

Value for money

74 High impact

The low-flush design and moderate supply offer fair convenience. Duplicate niacin entries and uncertain active release reduce the value of the stated amount.

Report analysis

Goals

Cardiovascular Support
Cardiovascular Support
Impact
Moderate effect
C- Goal FitC Strength of SupportD- CoverageA+ Formula Quality
Niacin · 500 mg

Inositol hexanicotinate is marketed as no-flush niacin, but it does not have the same reliable lipid effects as prescription-dose nicotinic acid. Its cardiovascular role is therefore narrower and less certain than the name may suggest.

The derivative and amount are clearly disclosed in a focused tablet. Anyone seeking treatment for abnormal cholesterol should not substitute it for clinician-directed lipid therapy.

Study evidence
Niacin Supportive 136 studies
Heart Health
Heart Health
Impact
Moderate effect
D- Goal FitC- Strength of SupportF CoverageB+ Formula Quality

Inositol hexanicotinate is marketed as no-flush niacin, but it does not reliably provide the lipid effects associated with prescription nicotinic acid. The large labeled amount therefore has weak evidence as practical cardiovascular support.

The formula is transparent and focused, yet it addresses only a speculative lipid pathway. It should not be treated as a substitute for clinically managed lipid therapy.

Study evidence
Niacin Supportive 105 studies

Ingredients

IngredientAmount per serving
Niacin (Inositol Hexanicotinate, Vitamin B3)
 500 mg
Inositol (Inositol Hexanicotinate)
 143 mg
Gluten Free Adults 18–50 Dairy Free Sugar Free Vegetarian
Report overview
Niacin (Inositol Hexanicotinate, Vitamin B3) · 500 mg OverallScore83
C Active Ingredient Quality & BioavailabilityA+ Dose, Safety & Label TransparencyA+ Value

The 500 mg inositol hexanicotinate dose provides a clearly labeled no-flush niacin option, though it is less aligned than nicotinic acid with lipid-focused use. The amount is practical for this derivative and the expected flush profile is easy to understand. Low serving cost offers good value despite the absence of special release technology or a verified branded source.

View ingredientView products
Loading alternative details
82 Performance

No Flush Niacin (Inositol Hexanicotinate) 800 mg

Life Extension
<p>Clearly named inositol hexanicotinate provides substantial flush-free niacin exposure with economical serving value. Compared with the original, it preserves the comfort-focused intent with a clearly identified and easier-to-assess vitamin B3 approach; however, its cardiovascular effects may be less direct and reliable than those of nicotinic acid.</p>
80 Performance

No Flush Niacin 500 mg

Natural Factors
<p>Transparent inositol hexaniacinate provides a substantial no-flush serving at practical cost. Compared with the original, it preserves the comfort-focused intent with a clearly identified and easier-to-assess vitamin B3 approach; however, the form may release niacin less directly than nicotinic acid and is not an equivalent lipid-focused option.</p>
80 Performance

No-Flush Niacin (Inositol Hexanicotinate) 500 mg

Solgar
<p>Clearly identified inositol hexanicotinate supports a comfort-focused no-flush approach with good serving value. Compared with the original, it preserves the comfort-focused intent with a clearly identified and easier-to-assess vitamin B3 approach; however, the form is less direct than nicotinic acid for cardiovascular purposes.</p>
86 Budget

Niacinamide B-3 100 mg

Source Naturals
<p>A clearly identified moderate niacinamide tablet offers simple non-flushing vitamin B3 support with excellent serving economics. Serving cost is lower than the original, but it does not provide nicotinic acid’s lipid-focused effects and complete excipient details are missing.</p>
82 Budget

Niacinamide 500 mg

NOW
<p>A simple niacinamide capsule provides clearly named non-flushing vitamin B3 with strong skin-goal alignment. Serving cost is lower than the original, but the amount remains high for routine nutrition and does not offer nicotinic acid’s lipid-related effects.</p>
80 Budget

Niacinamide 500 mg

Best Naturals
<p>Clearly identified niacinamide provides a non-flushing option with useful skin and NAD-metabolism alignment. Serving cost is lower than the original, but the amount is well above basic nutritional needs and is not equivalent to nicotinic acid for lipid-focused use.</p>
79 Value

Niacin Inositol Hexanicotinate 500 mg

Nature's Bounty
<p>Named inositol hexanicotinate provides substantial no-flush vitamin B3 exposure in a simple capsule. Its quality-adjusted serving economics and clearer active design support practical value compared with the original, although its lipid-related effects may be less direct than nicotinic acid despite the practical serving cost.</p>
76 Value

Flush-Free Niacin 500 mg

Bluebonnet
<p>A named inositol hexanicotinate capsule provides a generally comfortable flush-free option. Its quality-adjusted serving economics and clearer active design support practical value compared with the original, although the form has less reliable lipid-related effects and weaker value than several simpler alternatives.</p>
80 Value

Niacinamide

Thorne
<p>Clearly identified niacinamide provides a simple non-flushing option with strong skin-purpose alignment. Its lower serving cost and clearer active design support practical value compared with the original, although the amount is well above basic nutritional needs and is not a direct cardiovascular niacin substitute.</p>
Report alternatives

Sources

Published studies used for the product analysis and the top-ranked studies for each ingredient and goal.

  1. Effect of niacin therapy on cardiovascular outcomes in patients with coronary artery disease.
    Duggal JK; Singh M; Attri N; Singh PP; Ahmed N; Pahwa S; Molnar J; Singh S; Khosla S; Arora R · Journal of cardiovascular pharmacology and therapeutics · 2010
    Meta-analysis5,137 participants7 studies pooledHeart Health forNiacin
  2. Role of Niacin in Current Clinical Practice: A Systematic Review.
    Garg A; Sharma A; Krishnamoorthy P; Garg J; Virmani D; Sharma T; Stefanini G; Kostis JB; Mukherjee D; Sikorskaya E · The American journal of medicine · 2017
    Meta-analysis35,206 participants13 studies pooledHeart Health forNiacin
  3. Relationship of lipoproteins to cardiovascular events: the AIM-HIGH Trial (Atherothrombosis Intervention in Metabolic Syndrome With Low HDL/High Triglycerides and Impact on Global Health Outcomes).
    Guyton JR; Slee AE; Anderson T; Fleg JL; Goldberg RB; Kashyap ML; Marcovina SM; Nash SD; O'Brien KD; Weintraub WS; Xu P; Zhao XQ; Boden WE · Journal of the American College of Cardiology · 2013
    Randomized trial3,414 participantsHeart Health Cardiovascular Support forNiacin
  4. Assessment of the Role of Niacin in Managing Cardiovascular Disease Outcomes: A Systematic Review and Meta-analysis.
    D'Andrea E; Hey SP; Ramirez CL; Kesselheim AS · JAMA network open · 2020
    Meta-analysis35,760 participants17 studies pooledHeart Health forNiacin
  5. Exploring the Cardiovascular Impacts of Oral Nicotinamide: A Comprehensive Narrative Review.
    Shoukfeh R; Tisack AM; Lim HW; Mohammad TF · Journal of drugs in dermatology : JDD · 2025
    Narrative reviewHeart Health forNiacin
  6. The ARBITER 6-HALTS Trial (Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol 6-HDL and LDL Treatment Strategies in Atherosclerosis): final results and the impact of medication adherence, dose, and treatment duration.
    Villines TC; Stanek EJ; Devine PJ; Turco M; Miller M; Weissman NJ; Griffen L; Taylor AJ · Journal of the American College of Cardiology · 2010
    Randomized trial315 participantsHeart Health forNiacin
  7. Niacinamide: A B vitamin that improves aging facial skin appearance.
    Bissett DL; Oblong JE; Berge CA · Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.] · 2005
    Randomized trial50 participantsSkin Health forNiacin
  8. The effect of niacinamide on reducing cutaneous pigmentation and suppression of melanosome transfer.
    Hakozaki T; Minwalla L; Zhuang J; Chhoa M; Matsubara A; Miyamoto K; Greatens A; Hillebrand GG; Bissett DL; Boissy RE · The British journal of dermatology · 2002
    Randomized trial138 participantsSkin Health forNiacin
  9. Effect of Nicotinamide in Skin Cancer and Actinic Keratoses Chemoprophylaxis, and Adverse Effects Related to Nicotinamide: A Systematic Review and Meta-Analysis.
    Mainville L; Smilga AS; Fortin PR · Journal of cutaneous medicine and surgery · 2022
    Meta-analysis3,039 participants29 studies pooledSkin Health forNiacin
  10. Nicotinamide for Skin-Cancer Chemoprevention in Transplant Recipients.
    Allen NC; Martin AJ; Snaidr VA; Eggins R; Chong AH; Fernandéz-Peñas P; Gin D; Sidhu S; Paddon VL; Banney LA; Lim A; Upjohn E; Schaider H; Ganhewa AD; Nguyen J; McKenzie CA; Prakash S; McLean C; Lochhead A; Ibbetson J; Dettrick A; Landgren A; Allnutt KJ; Allison C; Davenport RB; Mumford BP; Wong B; Stagg B; Tedman A; Gribbin H; Edwards HA; De Rosa N; Stewart T; Doolan BJ; Kok Y; Simpson K; Low ZM; Kovitwanichkanont T; Scolyer RA; Dhillon HM; Vardy JL; Chadban SJ; Bowen DG; Chen AC; Damian DL · The New England journal of medicine · 2023
    Randomized trial158 participantsSkin Health forNiacin
  11. Evaluation of anti-wrinkle effects of a novel cosmetic containing niacinamide.
    Kawada A; Konishi N; Oiso N; Kawara S; Date A · The Journal of dermatology · 2008
    Randomized trial30 participantsSkin Health forNiacin
  12. A Foodborne Outbreak Traced to Niacin Overenrichment.
    Hudson PJ; Vogt RL · Journal of food protection · 2023
    Case-control study21 participantsSkin Health forNiacin
  13. Nicotinamide for Skin Cancer Chemoprevention.
    Breglio KF; Knox KM; Hwang J; Weiss R; Maas K; Zhang S; Yao L; Madden C; Xu Y; Hartman RI; Wheless L · JAMA dermatology · 2025
    Cohort study33,822 participantsSkin Health forNiacin
  14. Chemoprevention of keratinocyte carcinomas and actinic keratoses in adults who were immunocompetent: a systematic review.
    Susanto A; Morgan E; Lindsay D; Collins LG · Clinical and experimental dermatology · 2026
    Systematic review7,355 participants11 studies pooledSkin Health forNiacin
  15. The current state of niacin in cardiovascular disease prevention: a systematic review and meta-regression.
    Lavigne PM; Karas RH · Journal of the American College of Cardiology · 2013
    Meta-analysis9,959 participants11 studies pooledCardiovascular Support forNiacin
  16. Effects of niacin on apo A1 and B levels: a systematic review and meta-analysis of randomised controlled trials.
    Saboori S; Yousefi Rad E; Tammam J; Thondre PS; Coe S · The British journal of nutrition · 2024
    Meta-analysis12 studies pooledCardiovascular Support forNiacin
  17. Niacin improves lipid profile but not endothelial function in patients with coronary artery disease on high dose statin therapy.
    Philpott AC; Hubacek J; Sun YC; Hillard D; Anderson TJ · Atherosclerosis · 2013
    Randomized trial66 participantsCardiovascular Support forNiacin
  18. Supplemental Vitamins and Minerals for Cardiovascular Disease Prevention and Treatment: JACC Focus Seminar.
    Jenkins DJA; Spence JD; Giovannucci EL; Kim YI; Josse RG; Vieth R; Sahye-Pudaruth S; Paquette M; Patel D; Blanco Mejia S; Viguiliouk E; Nishi SK; Kavanagh M; Tsirakis T; Kendall CWC; Pichika SC; Sievenpiper JL · Journal of the American College of Cardiology · 2021
    Meta-analysisCardiovascular Support forNiacin
  19. Effect of niacin on lipid and lipoprotein levels and glycemic control in patients with diabetes and peripheral arterial disease: the ADMIT study: A randomized trial. Arterial Disease Multiple Intervention Trial.
    Elam MB; Hunninghake DB; Davis KB; Garg R; Johnson C; Egan D; Kostis JB; Sheps DS; Brinton EA · JAMA · 2000
    Randomized trial468 participantsCardiovascular Support forNiacin
  20. Effect of lipid-lowering therapies on lipoprotein(a) levels: a comprehensive meta-analysis of randomized controlled trials.
    Xie S; Galimberti F; Olmastroni E; Carugo S; Catapano AL; Casula M; META-LIPID Group · Atherosclerosis · 2025
    Meta-analysis145,314 participants147 studies pooledCardiovascular Support forNiacin
  21. Extended-release niacin vs gemfibrozil for the treatment of low levels of high-density lipoprotein cholesterol. Niaspan-Gemfibrozil Study Group.
    Guyton JR; Blazing MA; Hagar J; Kashyap ML; Knopp RH; McKenney JM; Nash DT; Nash SD · Archives of internal medicine · 2000
    Randomized trial173 participantsCardiovascular Support forNiacin
  22. Equivalent efficacy of a time-release form of niacin (Niaspan) given once-a-night versus plain niacin in the management of hyperlipidemia.
    Knopp RH; Alagona P; Davidson M; Goldberg AC; Kafonek SD; Kashyap M; Sprecher D; Superko HR; Jenkins S; Marcovina S · Metabolism: clinical and experimental · 1998
    Randomized trial223 participantsCardiovascular Support forNiacin
  23. Differential effect of two nicotinic acid preparations on low-density lipoprotein subclass distribution in patients classified as low-density lipoprotein pattern A, B, or I.
    Superko HR; McGovern ME; Raul E; Garrett B · The American journal of cardiology · 2004
    Randomized trial180 participantsHeart Health forNiacin
  24. The effects of extended-release niacin on carotid intimal media thickness, endothelial function and inflammatory markers in patients with the metabolic syndrome.
    Thoenes M; Oguchi A; Nagamia S; Vaccari CS; Hammoud R; Umpierrez GE; Khan BV · International journal of clinical practice · 2008
    Randomized trial50 participantsHeart Health forNiacin
  25. Effect of niacin on endothelial function: a systematic review and meta-analysis of randomized controlled trials.
    Sahebkar A · Vascular medicine (London, England) · 2014
    Meta-analysis441 participants7 studies pooledHeart Health forNiacin